According to Travere Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.16925. At the end of 2022 the company had a P/E ratio of -4.81.
Year | P/E ratio | Change |
---|---|---|
2022 | -4.81 | -53.02% |
2021 | -10.2 | 26.67% |
2020 | -8.09 | 97.06% |
2019 | -4.10 | -53.94% |
2018 | -8.91 | -34.88% |
2017 | -13.7 | -7.49% |
2016 | -14.8 | -376.77% |
2015 | 5.34 | -308.24% |
2014 | -2.57 | -12.02% |
2013 | -2.92 | -88.68% |
2012 | -25.8 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
OPKO Health
OPK | -4.67 | 299.12% | ๐บ๐ธ USA |
Onconova Therapeutics ONTX | -0.9953 | -14.88% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.